GYRE has been in the news 313% more than usual
Oct 27, 2025, 8:32 PM
-3.56%
What does GYRE do
Gyre Therapeutics, a San Diego-based biopharmaceutical company with 593 employees, focuses on developing F351 for treating NASH-associated fibrosis and has a pipeline through its indirect interest in Gyre Pharmaceuticals. The company went public on April 12, 2006, and also offers the drug ETUARY.
GYRE has been in the news recently: Novartis AG is set to acquire Avidity Biosciences for $12 billion, with the transaction expected to close in the first half of 2026. Following the announcement, Avidity's stock experienced a rise, marking it as one of the largest biotech deals of the year.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.